Please login to the form below

Not currently logged in
Email:
Password:

Lilly’s Cyramza disappoints in liver cancer

Fails to improve overall survival by significant margin
Eli Lilly HQ

Lilly's cancer drug Cyramza has continued its mixed history of clinical trial results after a disappointing performance in a liver cancer study.

The drug, which was approved this year to treat stomach cancer, was able to improve overall survival in patients with hepatocellular carcinoma compared to placebo, but not by a significant enough margin to hit the primary endpoint of the trial.

It was being investigated as a second-line treatment in patients who had already been treated with Bayer's Nexavar (sorafenib) in the first-line setting.

Cyramza (ramucirumab) was acquired by Lilly via its purchase of ImClone Systems in 2008 and the drug has been tipped as one of its main prospects in oncology due in part to its potential in a number of cancers.

In addition to its approval in stomach cancer, the drug has also demonstrated positive phase III data in lung cancer. However, Cyramza has already failed in a phase III trial investigating its use in breast cancer, and the latest results in liver cancer further restrict the drug's potential.

Despite the disappointing results, Richard Gaynor, senior VP product development and medical affairs for Lilly Oncology, discussed the possibility of the drug's use in a specific set of patients with liver cancer.

“We are encouraged by the efficacy seen overall, especially in specific subpopulations,” he said. “We plan to discuss these results with regulatory authorities."

No specifics were given about the subset of patients referenced by Gaynor, although Lilly intends to present data from the phase III REACH trial at a scientific meeting this year.

Lilly also plans to publish this year results of a trial investigating the use of Cyramza as treatment for metastatic colorectal cancer.

Article by
Thomas Meek

12th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics